Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,992,416 | $1,578,280 | $1,914,236 | $1,548,376 |
| - Cash | $69,331 | $75,054 | $93,120 | $203,434 |
| + Debt | $34,271 | $41,527 | $437,966 | $420,550 |
| Enterprise Value | $1,957,356 | $1,544,753 | $2,259,082 | $1,765,492 |
| Revenue | $661,817 | $607,521 | $667,238 | $579,775 |
| % Growth | 8.9% | -8.9% | 15.1% | – |
| Gross Profit | $583,911 | $523,742 | $580,017 | $504,714 |
| % Margin | 88.2% | 86.2% | 86.9% | 87.1% |
| EBITDA | $178,284 | $90,043 | $153,356 | $129,193 |
| % Margin | 26.9% | 14.8% | 23% | 22.3% |
| Net Income | $73,865 | $1,316 | $60,711 | $53,424 |
| % Margin | 11.2% | 0.2% | 9.1% | 9.2% |
| EPS Diluted | 1.32 | 0.024 | 1.04 | 0.98 |
| % Growth | 5,469.6% | -97.7% | 6.1% | – |
| Operating Cash Flow | $171,951 | $111,085 | $116,826 | $127,127 |
| Capital Expenditures | -$725 | -$551 | -$412 | -$2,045 |
| Free Cash Flow | $171,226 | $110,534 | $116,414 | $125,082 |